Wolfgang Miesbach: How SUMOylation Limits AAV Gene Therapy
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
”Gene therapy: same vector, same dose — up to 20 times more transgene.
Vector delivers the gene — the hepatocyte determines how efficiently it works.
At ISTH 2026, Denise Sabatino presented data identifying SUMOylation — a common host post-translational modification — as a restriction factor for transgene expression in AAV-transduced cells.
The agent: TAK-981 (subasumstat), a clinical-stage SUMO-activating enzyme inhibitor.
- In vitro: up to approximately 20 times higher transgene expression, across all cell types and promoters tested
- In vivo: around 36 times, 90 times and 200 times luciferase at days 1, 2 and 3
- Vector copy number lower while transgene mRNA and protein higher — driven not by increased vector uptake but by de-repression within the transduced cell
- Therapeutic transgenes: around 4 times FVIII (haemophilia A) and ~2× FIX-Padua (haemophilia B), including dosing months after transduction
- Effect transient and repeatable — a pharmacologically tunable intervention
SUMO-mediated restriction is an underappreciated limitation of AAV gene therapy, independent of serotype, promoter and transgene.
Modulating it may improve the durability and efficacy of expression — a relevant target for a field focused on long-term, predictable transgene output.”
Stay updated with Hemostasis Today.
-
Nov 9, 2026, 13:48PF4-ELISA–Negative HIT: Are We Missing a New Class of Anti-PF4 Immunothrombotic Disease?
-
Nov 9, 2026, 13:07Nandini Sadasivam: Gene Therapy for Sickle Cell Disease and Thalassaemia
-
Nov 9, 2026, 13:04Raising Awareness of Bleeding Disorders in Women and Girls – EHC
-
Nov 9, 2026, 12:59Rahul Bohra: Exploring the Complex Mechanisms of Sickle Cell Disease
-
Nov 9, 2026, 12:53Three Years of Movement and Thrombosis Awareness in the Czech Republic – World Thrombosis day
-
Nov 9, 2026, 12:51Octavio Marques Pontes-Neto: Intensive Blood-Pressure Control Reduces Cardiovascular Events After Ischemic Stroke
-
Nov 9, 2026, 12:49Irma Bagdoniene: What Really Makes Us Live Longer
-
Nov 9, 2026, 12:47Imo Akpan: Announcing the 2027 Women’s Hematology Summit
-
Nov 9, 2026, 12:45Shadi Yaghi: Rethinking Antithrombotic Therapy After Stroke